A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring

Running, not enrolling

Conditions studied: Psoriasis

In brief

This observational study aims to assess pregnancy and infant outcomes among pregnant women with psoriasis who have been exposed to deucravacitinib treatment in the USA.

Key facts

Study ID

NCT06710470

Run by

Bristol-Myers Squibb

People needed

833

Starts

2024-08-02

Expected to finish

2029-02-28

Last updated by the study team

2024-11-29

Who can join

Age: 15 and older, up to 50. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Maternal age 15 through 50 years at date of conception
• Start of pregnancy, defined as the estimated date of conception, during the accrual period (09-Sep-2022 through 31-Oct-2026)
• Continuous medical and pharmacy coverage for a minimum of 6 months prior to and including the estimated date of conception
• Presence of psoriasis from 12 months prior to the date of conception through the end of pregnancy

You may not qualify if…

• Exposure to any known teratogens from 5 half-lives prior to the estimated date of conception through the end of the relevant exposure window

Where it is running

• Bristol-Meyers Squibb — Lawrenceville, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.